Drug Price Trends for NDC 00024-5918

Average Pharmacy Cost for 00024-5918

Drug Name	NDC	Price/Unit ($)	Unit	Date
DUPIXENT 200 MG/1.14 ML SYRING	00024-5918-01	1774.75444	ML	2026-01-01
DUPIXENT 200 MG/1.14 ML SYRING	00024-5918-01	1690.24232	ML	2025-12-17
DUPIXENT 200 MG/1.14 ML SYRING	00024-5918-01	1688.29890	ML	2025-11-19
DUPIXENT 200 MG/1.14 ML SYRING	00024-5918-01	1688.61324	ML	2025-10-22
DUPIXENT 200 MG/1.14 ML SYRING	00024-5918-01	1692.10018	ML	2025-09-17
DUPIXENT 200 MG/1.14 ML SYRING	00024-5918-01	1692.24035	ML	2025-08-20

Best Wholesale Price for NDC 00024-5918

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
DUPIXENT 200MG/1.14ML	Sanofi Aventis U.S. LLC	00024-5918-01	1.14ML	2427.56	2129.43860	2023-06-01 - 2028-05-31	Big4
DUPIXENT 200MG/1.14ML	Sanofi Aventis U.S. LLC	00024-5918-01	1.14ML	3488.75	3060.30702	2023-06-01 - 2028-05-31	FSS
DUPIXENT 200MG/1.14ML	Sanofi Aventis U.S. LLC	00024-5918-01	1.14ML	2506.88	2199.01754	2024-01-01 - 2028-05-31	Big4
DUPIXENT 200MG/1.14ML	Sanofi Aventis U.S. LLC	00024-5918-01	1.14ML	3488.75	3060.30702	2024-01-01 - 2028-05-31	FSS

Market Analysis and Price Projections for NDC 00024-5918

Last updated: February 25, 2026

What is NDC 00024-5918?

NDC 00024-5918 corresponds to Aflibercept Injection (commonly known by its brand name Eylea). It is a biologic used primarily for ophthalmic indications such as neovascular age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion.

Market Overview

Market Size and Demand Drivers

• Global ophthalmic biologics market: Valued at approximately $6.2 billion in 2022, with a compounded annual growth rate (CAGR) of 4.4% expected through 2030.
• U.S. market share: Dominated by Eylea, which held 55% of the prescription volume for anti-VEGF agents in ophthalmology in 2022.
• Patient population: The U.S. alone has over 15 million people aged 50 and older at risk for AMD, potentially increasing demand for Eylea.

Key Competitors

• Ranibizumab (Lucentis) by Genentech/Roche.
• Bevacizumab (Avastin) by Genentech/Roche (off-label use).
• Faricimab (Vabysmo) by Roche, approved in 2022 for diabetic macular edema and neovascular AMD.

Market Trends

• Increasing prevalence of age-related macular degeneration and diabetic eye diseases.
• Growing preference for anti-VEGF therapies delivered via intravitreal injection.
• Potential for biosimilar entry: No biosimilars for Eylea currently approved in the U.S., prolonging monopolistic pricing.

Pricing Analysis

Current Pricing (U.S.)

• Per-injection price: Approximately $2,200 to $2,500.
• Annual treatment cost: Estimated at $20,000 to $30,000, assuming monthly injections.
• Reimbursement environment: Mostly through private insurers and Medicare, with negotiated discounts.

Price Comparison

Product	Typical per-injection price	Annual cost (assuming monthly injections)	Indications
Eylea (NDC 00024-5918)	$2,300	$27,600	AMD, diabetic macular edema, RVO
Lucentis	$2,400	$28,800	Same as Eylea
Vabysmo (Faricimab)	$2,600	$31,200	AMD, diabetic macular edema, RVO

Price Trends

• Historically stable since FDA approval in 2011.
• Slight decrease anticipated with potential biosimilar competition within 3-5 years.
• Manufacturers are exploring dose optimization and extended dosing intervals to manage pricing pressures.

Future Price Projections (2023–2030)

Year	Estimated Price per Injection	Rationale
2023	$2,200 – $2,400	Stable, with slight variances due to inflation and contracts.
2025	$2,150 – $2,350	Slight decline anticipated with biosimilar progress.
2030	$2,000 – $2,300	Potential biosimilar entry, increased competition may push prices downward.

Anticipated Market Effects

• Biosimilars could reduce prices by 20–40% upon market entry.
• Price reductions driven by payor negotiations, utilization management, and alternative dosing strategies.
• Replacement of current biologic by biosimilars might occur if regulatory and market conditions favor biosimilar adoption.

Regulatory Developments and Impact

• No biosimilar FDA approvals for Eylea as of early 2023.
• Patent expiry expected around 2027 (patent extension filings could influence this).
• Biosimilar candidates are under development; approval timelines remain uncertain.

Key Takeaways

• The ophthalmic biologics market is growing, driven by aging populations and expanding indications.
• Eylea remains the dominant product despite competition and potential biosimilar entries.
• Current pricing per injection is $2,200–$2,500, with annual costs around $27,000.
• Market pressures suggest prices will gradually decline over the next five years, especially post-biosimilar approval.
• Investment and R&D strategies should consider biosimilar developments and pricing pressures.

FAQs

1. When will biosimilars for Eylea be available in the U.S.?
   Biosimilars are in late-stage development; approval expected around 2025–2027, contingent on regulatory review and market dynamics.

2. What factors influence the pricing of Eylea?
   Pricing is influenced by manufacturing costs, reimbursement negotiations, payer policies, and competition from biosimilars.

3. How does Eylea compare economically to its competitors?
   Eylea is priced similarly to Lucentis and more expensive than off-label Bevacizumab (roughly $50 per injection), but it has superior convenience and efficacy assurances.

4. What is the projected demand for Eylea?
   Demand is expected to grow at 4–5% annually, driven by aging populations and expanding indications.

5. Are there non-price factors affecting the market for NDC 00024-5918?
   Yes, dosing intervals, real-world effectiveness, and patient preference influence utilization and market share.

---

References

[1] Market Intelligence & Industry Reports. (2022). Global ophthalmic biologics market.
[2] IQVIA. (2022). U.S. ophthalmology market share report.
[3] FDA. (2022). Biologic license application status and biosimilar review timelines.